Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis - PubMed (original) (raw)
Review
. 2017 Mar;176(3):594-603.
doi: 10.1111/bjd.14814. Epub 2016 Oct 13.
Affiliations
- PMID: 27292159
- DOI: 10.1111/bjd.14814
Review
Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis
F Gómez-García et al. Br J Dermatol. 2017 Mar.
Abstract
A new generation of biologics targeting the interleukin-23-T helper 17 pathway has been developed. This study aimed to assess the short-term effectiveness and safety of these new agents using a network meta-analysis. Twenty-seven randomized clinical trials (10 629 patients) were identified by a comprehensive systematic literature review (PROSPERO 2015: CRD42015025472). Quality of evidence was assessed following Cochrane-compliant rules and the Grading of Recommendations, Assessment, Development and Evaluations approach. Efficacy and safety outcomes at weeks 10-16 were compared using a random-effects network meta-analysis within a frequentist framework to estimate pooled odds ratios (ORs) of direct and indirect comparisons among the therapeutic options. There were six direct drug-to-drug comparisons in the network, with a high degree of consistency between the direct and indirect evidence. From the available evidence, infliximab 5 mg kg-1 every 8 weeks [OR 118·89, 95% confidence interval (CI) 60·91-232·04] and secukinumab 300 mg every 4 weeks (OR 87·07, 95% CI 55·01-137·82) are shown to be among the most effective short-term treatments, but are ranked as the biologics most likely to produce any adverse event or an infectious adverse event, respectively. Ustekinumab 90 mg every 12 weeks, the third most efficacious treatment (OR 73·67, 95% CI 46·97-115·56), was the only agent that did not show increased risk of adverse events compared with placebo. Treatment recommendations should also consider long-term outcomes and costs.
© 2016 British Association of Dermatologists.
Similar articles
- A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB. Bilal J, et al. J Dermatolog Treat. 2018 Sep;29(6):569-578. doi: 10.1080/09546634.2017.1422591. Epub 2018 Mar 28. J Dermatolog Treat. 2018. PMID: 29532693 Review. - Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A. Schmitt J, et al. Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663. Br J Dermatol. 2014. PMID: 24131260 Review. - Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K, Burden AD, Eaton JN, Hawkins NS. Reich K, et al. Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11. Br J Dermatol. 2012. PMID: 21910698 Review. - Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis.
Nast A, Jacobs A, Rosumeck S, Werner RN. Nast A, et al. J Invest Dermatol. 2015 Nov;135(11):2641-2648. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5. J Invest Dermatol. 2015. PMID: 26046458 Review. - Severe and acute complications of biologics in psoriasis.
Oussedik E, Patel NU, Cash DR, Gupta AS, Feldman SR. Oussedik E, et al. G Ital Dermatol Venereol. 2017 Dec;152(6):586-596. doi: 10.23736/S0392-0488.17.05750-9. Epub 2017 Sep 12. G Ital Dermatol Venereol. 2017. PMID: 28895664 Review.
Cited by
- Short term efficacy of biological treatment for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.
Ismail O, Jaber K, Jaber Y, Froukh U, Younis A, Albdour K, Momani Y, Almaani N. Ismail O, et al. Arch Dermatol Res. 2024 Oct 18;316(10):699. doi: 10.1007/s00403-024-03398-y. Arch Dermatol Res. 2024. PMID: 39424649 - Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, Naldi L, Kinberger M, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2023 Jul 12;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6. Cochrane Database Syst Rev. 2023. PMID: 37436070 Free PMC article. Review. - Is Th17-Targeted Therapy Effective in Systemic Lupus Erythematosus?
Petrić M, Radić M. Petrić M, et al. Curr Issues Mol Biol. 2023 May 15;45(5):4331-4343. doi: 10.3390/cimb45050275. Curr Issues Mol Biol. 2023. PMID: 37232744 Free PMC article. Review. - Methods used for indirect comparisons of systemic treatments for psoriasis. A systematic review.
Nast A, Dressler C, Schuster C, Saure D, Augustin M, Reich K. Nast A, et al. Skin Health Dis. 2022 Apr 23;3(1):e112. doi: 10.1002/ski2.112. eCollection 2023 Feb. Skin Health Dis. 2022. PMID: 36751312 Free PMC article. Review. - Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review.
Ayen-Rodríguez A, Pereyra-Rodríguez JJ, Navarro-Triviño FJ, Alcantara-Luna S, Domínguez-Cruz J, Galán-Gutiérrez M, Vilar-Palomo S, Armario-Hita JC, Ruiz-Villaverde R. Ayen-Rodríguez A, et al. Life (Basel). 2022 Jul 30;12(8):1159. doi: 10.3390/life12081159. Life (Basel). 2022. PMID: 36013338 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical